Inside Else Nutrition’s CFO shuffle: What Natie Zilberberg’s appointment means for capital strategy in 2026

Else Nutrition Holdings Inc. (TSXV: BABY) has appointed Natie Zilberberg as its new Chief Financial Officer, effective immediately. The appointment follows the departure of Steve Lemisch, who had served as CFO since September 2022. This internal promotion places a longtime board member and former interim CEO in charge of the company’s financial strategy at a time when Else Nutrition is seeking to scale its U.S. distribution footprint and stabilize its capital structure amid ongoing losses.

Zilberberg will continue serving on Else Nutrition’s board of directors while assuming day-to-day financial leadership responsibilities. The dual role reflects a broader pattern of consolidation across the company’s leadership ranks since the appointment of Michael Azoulay as interim CEO in late 2025. The transition comes as the plant-based pediatric nutrition company enters what it describes as the “second phase” of its growth strategy—focused on monetizing channel expansion, increasing gross margins, and securing long-term funding pathways.

Why is Else Nutrition relying on an internal CFO appointment instead of external financial leadership?

The choice of Natie Zilberberg as CFO signals a strong preference for internal continuity over external transformation. Zilberberg’s deep familiarity with Else Nutrition’s strategic history, operational hurdles, and capital constraints allows him to hit the ground running without a prolonged onboarding period. His prior role as interim CEO, as well as long tenure on the board, has kept him close to the company’s commercial execution and investor dialogue.

While the appointment may raise some governance questions around board–executive role separation, the company appears to be prioritizing short-term financial discipline and alignment over structural orthodoxy. For a company like Else Nutrition, which has struggled with capital inefficiency, inventory volatility, and unpredictable revenue cycles, internal alignment across board and management could serve as a hedge against execution missteps.

Zilberberg’s prior experience at companies such as Gadot Biochemical Industries Ltd. and Algatechnologies Ltd. brings added credibility to the financial oversight function, particularly in nutraceutical and health-adjacent industries. His understanding of global distribution, ingredient supply chains, and specialty nutrition markets may also support operational streamlining and procurement rationalization as the company seeks to reduce costs and improve gross margins.

What does the CFO change indicate about Else Nutrition’s capital allocation and funding runway?

Else Nutrition remains a pre-profit, cash-burning company with limited visibility into self-sustaining operations. The company’s most recent quarterly filings indicated ongoing net losses, modest sequential revenue growth, and negative gross margins. While product shelf placements and online availability have expanded—especially through CVS Pharmacy, Walmart, Amazon, and the company’s direct-to-consumer website—the unit economics of these sales have yet to demonstrate scalability.

In this environment, the CFO role becomes central not just for compliance and reporting, but as the architect of capital survival. Else Nutrition’s cash runway is periodically extended through equity issuance and convertible securities, a strategy that places added pressure on the CFO to maintain investor confidence while limiting dilution.

The internal appointment of Zilberberg could be interpreted as a signal that the company is not planning a near-term major capital markets transaction, such as a secondary raise or uplisting effort, that would require an externally visible finance executive. However, it could also reflect the difficulty of attracting external CFO talent to a high-risk, thinly capitalized small-cap firm without a clear path to profitability.

Zilberberg’s appointment may also give him greater influence over operational budgeting and SG&A controls, both of which will be necessary to slow the company’s burn rate. The strategic imperative for Else Nutrition is not simply to grow top-line revenue but to demonstrate gross margin traction, channel velocity, and working capital discipline—areas where CFO oversight will be critical.

How does this fit into Else Nutrition’s broader U.S. market strategy?

Else Nutrition is positioning itself as a challenger brand in the U.S. pediatric nutrition market, which has historically been dominated by large multinationals such as Abbott Laboratories, Reckitt Benckiser Group plc (through its Mead Johnson division), and Nestlé. The company offers a differentiated product line focused on clean-label, dairy-free, and soy-free toddler formulas, baby cereals, and kids’ nutritional shakes, all derived from whole food plant-based ingredients.

Its U.S. market entry began in earnest in 2022, with a direct-to-consumer strategy that has since evolved into a hybrid omnichannel model. The company has announced distribution deals with leading retail chains and pharmacy networks, but the transition from shelf placement to sales velocity has not been linear. Retail rollout has required significant upfront investment in trade promotion, co-marketing, and logistics—all of which stress the balance sheet while delaying margin realization.

The CFO’s job in this context is to ensure the company does not outgrow its financial foundation. That means refining forecasting tools, enforcing inventory discipline, and optimizing customer acquisition costs across both digital and retail channels. It also means establishing realistic internal benchmarks for new product launches and ensuring that capital is allocated toward the highest-return categories and markets.

Zilberberg’s dual role as board member may also streamline board-level buy-in for necessary pivots or cost-cutting initiatives if some channels underperform expectations.

What are the risks of board–executive role overlap for a company in Else Nutrition’s position?

While the dual role may improve agility and information flow between management and the board, it introduces a potential conflict of interest in the context of governance best practices. Most public companies seek to separate financial oversight (board-level audit committees) from financial execution (management CFOs), particularly when transparency and fiduciary discipline are paramount.

For Else Nutrition, the overlap could attract scrutiny if performance falters or if related-party decisions come into play. For example, should the company consider asset sales, restructuring, or financing from related entities, the lack of clear independence could become a red flag for auditors or regulators.

However, in practice, micro-cap companies like Else Nutrition often lean on existing board relationships for continuity and cost efficiency. The strategic tradeoff lies in whether the benefits of alignment and speed outweigh the long-term risks of blurred accountability—especially if the company intends to scale toward institutional investment or dual-listing in more stringent jurisdictions.

What does this leadership move signal for peers in the clean-label pediatric nutrition segment?

Else Nutrition’s trajectory mirrors many small-cap functional nutrition startups that emerged in the 2020s: compelling mission, science-backed formulations, credible shelf presence—but persistent difficulty converting traction into durable margins. The category is notoriously tough to scale, especially without vertical integration or a strong global licensing model.

Larger players like Hain Celestial Group Inc. have exited or de-emphasized pediatric categories due to regulatory complexity and margin challenges. Meanwhile, challenger brands like Serenity Kids and Bobbie (in the U.S. infant formula space) have focused tightly on specific age groups or channel niches rather than full-spectrum product portfolios.

Else Nutrition’s CFO reshuffle reflects the financial and strategic pressure facing firms that attempt to scale horizontally across categories and markets. For its peers, the takeaway is clear: success in pediatric nutrition hinges not only on formulation and branding but on supply chain control, financial agility, and investor trust.

Could this move open the door to strategic partnerships or M&A down the line?

Zilberberg’s background in M&A and board-level corporate development makes it plausible that Else Nutrition could explore partnerships, licensing deals, or partial asset sales if market conditions tighten. The CFO’s remit now includes both managing cash flow and positioning the company for long-term strategic options—particularly if organic growth continues to outpace capital availability.

This could include licensing its proprietary formulations to larger CPGs looking for clean-label expansion, partnering with pediatric clinics or hospitals for direct channel access, or even exploring global joint ventures in markets with high lactose intolerance or demand for plant-based alternatives.

Given the capital intensity of scaling pediatric nutrition, Else Nutrition may ultimately need a strategic partner with broader manufacturing and distribution capabilities to fully realize its vision. The CFO appointment may be the first step in preparing for such conversations.

What this CFO appointment means for Else Nutrition and the broader specialty nutrition sector

• Else Nutrition Holdings Inc. has named longtime board member and former interim CEO Natie Zilberberg as Chief Financial Officer.

• The internal promotion underscores a desire for leadership continuity, operational alignment, and cost discipline during a high-burn growth phase.

• Zilberberg brings experience from nutraceutical, biochemical, and M&A-intensive roles, aligning with the company’s need for capital agility and operational streamlining.

• The dual board–executive structure may raise governance flags but could offer execution speed in a resource-constrained environment.

• The company’s U.S. market strategy depends on converting shelf presence at major chains into repeat purchasing behavior and margin-positive sales.

• CFO priorities will likely include burn rate management, cash flow forecasting, cost containment, and retail sell-through optimization.

• Strategic partnerships or licensing deals could emerge as viable pathways to scale if capital market conditions remain tight.

• Peer companies in the pediatric and specialty nutrition sectors will be watching closely to see if this internal leadership reset improves financial performance in 2026.